Editorial Revisado por pares

Prime Editing: A Novel Cas9-Reverse Transcriptase Fusion May Revolutionize Genome Editing

2019; Mary Ann Liebert, Inc.; Volume: 30; Issue: 12 Linguagem: Inglês

10.1089/hum.2019.29098.trf

ISSN

1557-7422

Autores

Terence R. Flotte, Guangping Gao,

Tópico(s)

Pluripotent Stem Cells Research

Resumo

Human Gene TherapyVol. 30, No. 12 EditorialsPrime Editing: A Novel Cas9-Reverse Transcriptase Fusion May Revolutionize Genome EditingTerence R. Flotte and Guangping GaoTerence R. FlotteEditors-in-ChiefSearch for more papers by this author and Guangping GaoEditors-in-ChiefSearch for more papers by this authorPublished Online:16 Dec 2019https://doi.org/10.1089/hum.2019.29098.trfAboutSectionsView articleView Full TextPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail View article"Prime Editing: A Novel Cas9-Reverse Transcriptase Fusion May Revolutionize Genome Editing." Human Gene Therapy, 30(12), pp. 1445–1446FiguresReferencesRelatedDetailsCited byPrime Editing, a Novel Genome-Editing Tool That May Surpass Conventional CRISPR-Cas9 Adriana Ochoa-Sanchez, Gabriela Perez-Sanchez, A. Marianna Torres-Ledesma, Juan Pablo R. Valdez, Gabriel Rinaldi, Bárbara B. Moguel, and Christian Molina-Aguilar14 October 2021 | Re:GEN Open, Vol. 1, No. 1 Volume 30Issue 12Dec 2019 InformationCopyright 2019, 2019 by Mary Ann Liebert, Inc., publishersTo cite this article:Terence R. Flotte and Guangping Gao.Prime Editing: A Novel Cas9-Reverse Transcriptase Fusion May Revolutionize Genome Editing.Human Gene Therapy.Dec 2019.1445-1446.http://doi.org/10.1089/hum.2019.29098.trfPublished in Volume: 30 Issue 12: December 16, 2019PDF download

Referência(s)
Altmetric
PlumX